Moomoo AI 已提取核心信息
Altamira Therapeutics Ltd. has officially requested the United States Securities and Exchange Commission (SEC) to declare its Registration Statement on Form F-3 effective by 5:00 p.m. Eastern Time on January 19, 2024. The request, made in accordance with Rule 461 under the Securities Act of 1933, as amended, was submitted through a correspondence dated January 17, 2024. The company's legal representative, Alex Dinur of Lowenstein Sandler LLP, is the point of contact for the SEC to confirm the effectiveness of the Registration Statement or to address any inquiries.
Altamira Therapeutics Ltd. has officially requested the United States Securities and Exchange Commission (SEC) to declare its Registration Statement on Form F-3 effective by 5:00 p.m. Eastern Time on January 19, 2024. The request, made in accordance with Rule 461 under the Securities Act of 1933, as amended, was submitted through a correspondence dated January 17, 2024. The company's legal representative, Alex Dinur of Lowenstein Sandler LLP, is the point of contact for the SEC to confirm the effectiveness of the Registration Statement or to address any inquiries.
Altamira Therapeutics Ltd.已正式要求美国证券交易委员会（SEC）在东部时间2024年1月19日下午5点之前宣布其F-3表格的注册声明生效。该请求是根据经修订的1933年《证券法》第461条提出的，是通过2024年1月17日的信函提交的。该公司的法定代表人，洛文斯坦·桑德勒律师事务所的亚历克斯·迪努尔是美国证券交易委员会的联系人，负责确认注册声明的有效性或处理任何查询。
Altamira Therapeutics Ltd.已正式要求美国证券交易委员会（SEC）在东部时间2024年1月19日下午5点之前宣布其F-3表格的注册声明生效。该请求是根据经修订的1933年《证券法》第461条提出的，是通过2024年1月17日的信函提交的。该公司的法定代表人，洛文斯坦·桑德勒律师事务所的亚历克斯·迪努尔是美国证券交易委员会的联系人，负责确认注册声明的有效性或处理任何查询。
有用
没用
该公告为独立文件：